Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19926761 | 1.00 | ALDH1A1 (0.33) | ALDH1A1OPRM1SMN1; SMN2SPHK1TRPV1 | |
| SCHEMBL1052850 | 0.80 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL17339702 | 0.79 | OPRM1 (0.32) | ALDH1A1OPRM1SPHK1TRPV1TRPA1 | |
| SCHEMBL2066948 | 0.77 | ALDH1A1 (0.35) | ALDH1A1OPRM1 | |
| SCHEMBL5269000 | 0.76 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL21118226 | 0.75 | METAP1 (0.43) | ALDH1A1OPRM1SPHK1 | |
| SCHEMBL3988178 | 0.75 | — | — | |
| SCHEMBL9720187 | 0.74 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11327617 | 0.73 | TRPV1 (0.33) | ALDH1A1TRPV1TRPA1 | |
| Fluoride SCHEMBL11473571 | 0.73 | TRPV1 (0.33) | ALDH1A1TRPV1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12077606-B2 | Cyclic peptide analogs and conjugates thereof | SIRENAS LLC (US) | 2024-09-03 | — | — | US | disclosed |
| US-20220227808-A1 | CYCLIC PEPTIDE ANALOGS AND CONJUGATES THEREOF | SIRENAS LLC | 2022-07-21 | — | — | US | disclosed |
| US-11254705-B2 | Cyclic peptide analogs and conjugates thereof | SIRENAS LLC (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254705-B2 | Cyclic peptide analogs and conjugates thereof | SIRENAS LLC (US) | 2022-02-22 | — | — | US | disclosed |
| US-20190211060-A1 | CYCLIC PEPTIDE ANALOGS AND CONJUGATES THEREOF | SIRENAS LLC (US) | 2019-07-11 | — | — | US | disclosed |
| US-20190211060-A1 | CYCLIC PEPTIDE ANALOGS AND CONJUGATES THEREOF | SIRENAS LLC (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211060-A1 | CYCLIC PEPTIDE ANALOGS AND CONJUGATES THEREOF | VIP, NGLY1, GRPR | ALDH1A1 4327/4885OPRM1 2150/4885SMN1; SMN2 3403/4885 |
| US-11254705-B2 | Cyclic peptide analogs and conjugates thereof | VIP, NGLY1, GRPR | ALDH1A1 4327/4885OPRM1 2150/4885SMN1; SMN2 3403/4885 |
| US-12077606-B2 | Cyclic peptide analogs and conjugates thereof | VIP, NGLY1, GRPR | ALDH1A1 4327/4885OPRM1 2150/4885SMN1; SMN2 3403/4885 |
| US-20220227808-A1 | CYCLIC PEPTIDE ANALOGS AND CONJUGATES THEREOF | VIP, NGLY1, GRPR | ALDH1A1 4327/4885OPRM1 2150/4885SMN1; SMN2 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.